Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Valeant Pharmaceuticals Intl (VRX)

Valeant Pharmaceuticals Intl (VRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,159,814
  • Shares Outstanding, K 348,710
  • Annual Sales, $ 8,724 M
  • Annual Income, $ 2,404 M
  • 60-Month Beta -0.38
  • Price/Sales 0.97
  • Price/Cash Flow 1.87
  • Price/Book 1.80
Trade VRX with:
  • Price/Earnings ttm 6.12
  • Earnings Per Share ttm 3.96
  • Most Recent Earnings 0.89 on 05/08/18
  • Next Earnings Date 08/14/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 1.000 on 11/10/10
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/18
See More
  • Average Estimate 0.81
  • Number of Estimates 6
  • High Estimate 0.91
  • Low Estimate 0.71
  • Prior Year 1.05
  • Growth Rate Est. (year over year) -22.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.56 +3.72%
on 06/28/18
27.25 -14.13%
on 06/14/18
-3.46 (-12.88%)
since 06/13/18
3-Month
16.76 +39.62%
on 04/16/18
27.79 -15.80%
on 06/13/18
+6.25 (+36.44%)
since 04/13/18
52-Week
10.94 +113.89%
on 11/02/17
27.79 -15.80%
on 06/13/18
+6.11 (+35.34%)
since 07/13/17

Most Recent Stories

More News
Bausch + Lomb Announces Statistically Significant Topline Results From The First Phase 3 Trial Of NOV03 (perfluorohexyloctane) In Dry Eye Disease Associated With Meibomian Gland Dysfunction

and , , /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), and Novaliq GmbH, a biopharmaceutical company...

VRX : 23.40 (-3.43%)
BHC : 28.39 (+0.64%)
BHC.TO : 36.27 (+0.36%)
Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance

, /PRNewswire/ --

VRX : 23.40 (-3.43%)
BHC : 28.39 (+0.64%)
BHC.TO : 36.27 (+0.36%)
Bausch Health Licenses Eyenovia's Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12

and , /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), Bausch + Lomb, its leading global eye health business, and Eyenovia, Inc., (NASDAQ: EYEN) ("Eyenovia"), a clinical...

VRX : 23.40 (-3.43%)
EYEN : 4.57 (+3.86%)
Bausch Health To Participate At The 18th Annual Morgan Stanley Global Healthcare Conference

, /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that , chairman and CEO; , senior vice president and corporate controller; and , senior vice president and head of Investor...

MS : 100.80 (+2.54%)
VRX : 23.40 (-3.43%)
Bausch Health Resolves Legacy SEC Investigation

, /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), f/k/a Valeant Pharmaceuticals International, Inc. ("Valeant"), today announced the successful resolution...

VRX : 23.40 (-3.43%)
Bausch Health To Participate At Goldman Sachs Annual Global Healthcare Conference

, /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that  Joseph C. Papa, chairman and chief executive officer, and , senior vice president and head of Investor Relations...

VRX : 23.40 (-3.43%)
Bausch Health Announces 2020 Annual Meeting Of Shareholder Results

, /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced the election of the eleven directors nominated at its 2020 annual meeting of shareholders...

VRX : 23.40 (-3.43%)
VRX Investor Alert: Kyros Law is Filing Legal Claims on Behalf of Valeant Pharmaceuticals (NYSE: VRX), now Bausch Health Companies (NYSE: BHC) Investors

Kyros Law Offices is alerting investors of Valeant Pharmaceuticals (NYSE: VRX), now Bausch Health Companies (NYSE: BHC) that it is filing legal claims against the company on behalf of investors.

VRX : 23.40 (-3.43%)
BHC : 28.39 (+0.64%)
Bausch Health Announces It Is Seeking A Refinancing Amendment To Its Existing Credit Agreement And Conditional Redemption Of Existing Senior Secured Notes

Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it is seeking to amend and refinance its existing credit agreement (the "Credit Agreement") in order...

VRX : 23.40 (-3.43%)
Ortho Dermatologics Opens 2020 Aspire Higher Scholarship Program

Students Treated for Dermatologic Conditions Can Apply for the Scholarship Through April 27, 2020

VRX : 23.40 (-3.43%)

Business Summary

Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients....

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 24.80
1st Resistance Point 24.10
Last Price 23.40
1st Support Level 23.03
2nd Support Level 22.66
3rd Support Level N/A

See More

52-Week High 27.79
Last Price 23.40
Fibonacci 61.8% 21.35
Fibonacci 50% 19.36
Fibonacci 38.2% 17.38
52-Week Low 10.94

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar